Vogenx (VOGX)
Develops an oral SGLT1 inhibitor for post-bariatric hypoglycemia.
$26.55
vs last close−0.02 (−0.08%)
Something off on this page? Send us feedback.
EPSReportedEstimate
———————Sep '26
Reported———————−$0.07
Estimate———————−$0.07
Surprise———————0.0%
RevenueReportedEstimate
———————Sep '26
Reported————————
Estimate————————
Surprise————————
History
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | −$0.07 | −$0.07 | 0.0% |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | −$0.07 | −$0.07 | 0.0% | — | — | — | −4.8% |